Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

BioArctic AB (BIOA B) NPV

Sell:93.90 SEK Buy:94.20 SEK Change: 1.10 SEK (1.18%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
Sell:93.90 SEK
Buy:94.20 SEK
Change: 1.10 SEK (1.18%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
Sell:93.90 SEK
Buy:94.20 SEK
Change: 1.10 SEK (1.18%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Contact details

Warfvinges vag 35
112 51
+46 (8) 6956930

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
6.84 billion SEK
Shares in issue:
88.06 million
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Wenche Rolfsen
    Independent Chairman of the Board
  • Gunilla Osswald
    Chief Executive Officer
  • Ivar Verner
    Independent Deputy Chairman of the Board
  • Lars Lannfelt
    Founder, Director, Senior Vice President University Collaborations
  • Jan Mattsson
    Chief Financial Officer, Vice President - Finance
  • Christer Moller
    Vice President Pre-Clinical Development, Chief Scientific Officer
  • Oskar Bosson
    Vice President of Communications & IR
  • Johanna Falting
    Vice President Translational Science & Pharmacology
  • Mikael Moge
    Vice President of Chemistry, Manufacturing & Control and Protein Chemistry
  • Nora Sjodin
    Vice President Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.